Get the Stockscreener App
76.10
1.01%
-0.78
After Hours:
76.10
Inhibrx Biosciences Inc stock is traded at $76.10, with a volume of 201.53K.
It is down -1.01% in the last 24 hours and down -14.94% over the past month.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
See More
Previous Close:
$76.88
Open:
$75.8
24h Volume:
201.53K
Relative Volume:
0.52
Market Cap:
$1.11B
Revenue:
$1.80M
Net Income/Loss:
$1.76B
P/E Ratio:
0.6413
EPS:
118.674
Net Cash Flow:
$-149.23M
1W Performance:
-2.41%
1M Performance:
-14.94%
6M Performance:
+366.01%
1Y Performance:
+360.65%
1-Day Range:
$75.38
$78.65
1-Week Range:
$74.46
$82.34
52-Week Range:
$10.80
$94.56
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Name
Inhibrx Biosciences Inc
Sector
Industry
Phone
(858) 795-4220
Address
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
76.10 | 1.12B | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-24 | Initiated | JMP Securities | Mkt Perform |
| Jan-23-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Mar-16-22 | Initiated | SMBC Nikko | Outperform |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Credit Suisse | Outperform |
| Sep-14-20 | Initiated | Evercore ISI | Outperform |
View All
Inhibrx Biosciences Inc Stock (INBX) Latest News
Understanding the Setup: (INBX) and Scalable Risk - Stock Traders Daily
What drives Inhibrx Biosciences Inc stock priceEarnings Per Share Trends & Missed Nvidia? Don’t Miss This One - earlytimes.in
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Sees Large Decline in Short Interest - MarketBeat
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts - Insider Monkey
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 7.2% – Here’s Why - Defense World
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 7.2%Should You Buy? - MarketBeat
Why Inhibrx's Recent Strength May Not Be Built to LastInhibrx Biosciences (NASDAQ:INBX) - Benzinga
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 7.9%Here's Why - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 1-Year HighHere's Why - MarketBeat
Is Inhibrx Biosciences (NASDAQ:INBX) A Risky Investment? - 富途牛牛
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Why Inhibrx Biosciences Inc. stock could rally in 2025July 2025 Market Mood & Fast Gain Stock Tips - Улправда
Is Inhibrx Biosciences Inc. stock trading at a premium valuation2025 Dividend Review & Low Risk Investment Opportunities - bolumsonucanavari.com
Buyout Rumor: How Inhibrx Biosciences Inc. stock benefits from tech adoptionWall Street Watch & High Yield Equity Trading Tips - ulpravda.ru
Can Inhibrx Biosciences Inc. stock deliver surprise earnings beatJuly 2025 Update & Accurate Trade Setup Notifications - DonanımHaber
Can Inhibrx Biosciences Inc. stock withstand economic slowdownWeekly Trend Recap & Short-Term Trading Alerts - DonanımHaber
How Inhibrx Biosciences Inc. stock benefits from tech adoptionJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Inhibrx Biosciences Inc. stock deliver consistent dividends2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates - Yahoo Finance
Inhibrx Biosciences (INBX): Assessing Valuation After New Oncology Pipeline and FDA Milestone Updates - Sahm
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - The Malaysian Reserve
Citizens reiterates Market Perform rating on Inhibrx Biosciences stock citing limited data disclosures - Investing.com Canada
Inhibrx Biosciences, Inc provides progress updates on the Inbrx-106 program and the expansion cohorts of the Ozekibart (Inbrx-109) program - marketscreener.com
Inhibrx Biosciences Announced An Update On The INBRX-106 Phase 2/3 Clinical Trial In Combination With Keytruda; Inhibrx Expects To Complete Enrollment In The Phase 2 Portion Of The Trial During The First Quarter Of 2026 - Sahm
Inhibrx Biosciences Provides Updates on Clinical Trials - TradingView — Track All Markets
[8-K] Inhibrx Biosciences, Inc. Reports Material Event | INBX SEC FilingForm 8-K - Stock Titan
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 6.6%Here's Why - MarketBeat
Inhibrx Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
EDGAR Filing Documents for 0002007919-25-000093 - SEC.gov
Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. $INBX - MarketBeat
Why Is INBX Stock Rising Today? - MSN
Franklin Resources Inc. Makes New $316,000 Investment in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences advances sarcoma research with ozekibart trial results - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5%Here's What Happened - MarketBeat
Inhibrx Biosciences, Inc. $INBX Shares Acquired by Kennedy Capital Management LLC - MarketBeat
With Inhibrx Biosciences Stock Surging, Have You Considered The Downside? - Trefis
Inhibrx Biosciences (NASDAQ:INBX) Trading 6.8% HigherWhat's Next? - MarketBeat
Is Inhibrx Biosciences Inc. stock a buy on dipsDollar Strength & Real-Time Market Trend Scan - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD By Investing.com - Investing.com Nigeria
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week HighHere's Why - MarketBeat
Why Inhibrx Biosciences Inc. stock is favored by top institutions2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - Newser
Inhibrx Biosciences stock hits all-time high at 87.89 USD - Investing.com
Avoiding Lag: Real-Time Signals in (INBX) Movement - news.stocktradersdaily.com
Inhibrx Biosciences boosts MSTS 2025 with platinum sponsorship - Traders Union
Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) - Aktiellt
Earnings Report: How sustainable is Inhibrx Biosciences Inc. stock dividend payoutBond Market & AI Enhanced Trading Alerts - BỘ NỘI VỤ
Inhibrx Biosciences unveils preclinical progress in glioblastoma treatment - Traders Union
Inhibrx Biosciences (NASDAQ:INBX) Sets New 1-Year HighHere's Why - MarketBeat
Inhibrx Biosciences Inc Stock (INBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):